Date: 2011-01-21
Type of information: Fundraising
Company: InDex Pharmaceuticals (Sweden)
Investors: Industrifonden (Sweden) - current investors - SEB Venture Capital
Amount: SEK 75 million (€8.35 million)
Funding type: financing round
Planned used: The financing will in large be used to conduct a clinical phase III trial using Kappaproct®with the aim of obtaining market approval. In the planned phase III trial, Kappaproct® will be used to treat severe ulcerative colitis patients who have failed all other medical treatments and have only radical surgery as a remaining treatment option. Kappaproct is used in combination with traditional medication restoring the effect of the latter and allowing the patient to avoid surgery.
Others: Industrifonden has invested MSEK 40 and becomes a new shareholder in InDex Pharmaceuticals, Current shareholders, including SEB Venture Capital, invest an additional MSEK 35.
Therapeutic area: Autoimmune diseases – Inflammatory diseases
